Phase 4
N=35
Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone
Gender Dysphoria, Adolescent
Bottom Line
View on ClinicalTrials.gov: NCT05726903 ↗Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Number of Participants Satisfied With Self-Administered DMPA at Initiation — 17 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Depo-subQ Provera Injectable Product (Drug)
- Age
- Pediatric, Adult · 15+ yrs
- Sex
- Female
- Sponsor
- University of Colorado, Denver
- Primary completion
- Nov 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Satisfied With Self-Administered DMPA at Initiation |
17 | — |
| PRIMARY Number of Participants Satisfied With DMPA in an Office Setting |
4 | — |
Summary
Recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (TGD) youth compared to cis-gender youth. Limited existing literature demonstrates the need for contraceptive counseling that moves beyond cis- and heteronormative assumptions that start with pregnancy prevention and address concerns at the intersection of gender identity.
The Investigator's qualitative study will focus on creating best practices regarding equitable contraceptive counseling for TGD youth. The Investigator will recruit transgender youth who are assigned female at birth, and currently or interested in using depo medroxyprogesterone (DMPA). Through focus groups and semi-structured interviews, the investigator hopes to guide providers in creating best practices and more equitable contraceptive counseling for TGD youth and measure satisfaction of DMPA in TGD youth.
Eligibility Criteria
Inclusion Criteria
- between the ages of 15-21,
- currently receiving care at one of the clinic sites, assigned female at birth, identify as transgender or gender diverse , and are currently using or are interested in using DMPA.
Exclusion Criteria
- Any contraindications to DMPA (based on any category 3 or 4 recommendations from the CDC MEC guidelines)
Data sourced from ClinicalTrials.gov (NCT05726903). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.